Iron-mediated cardiovascular injury

Vascular Medicine

Volumn 4, Issue 2, 1999, Pages 93-99

  Horwitz, Lawrence D ^a   Rosenthal, Eli A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Free radicals; Iron and atherosclerosis; Iron overload; Reperfusion injury

Indexed keywords

ANTHRACYCLINE; FREE RADICAL; IRON;

ATHEROGENESIS; BETA THALASSEMIA; CARDIOTOXICITY; CHELATION THERAPY; CORONARY ARTERY ATHEROSCLEROSIS; HEMOCHROMATOSIS; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHLEBOTOMY; PRIORITY JOURNAL; REPERFUSION INJURY; RESTENOSIS; REVIEW;

EID: 0033067885     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x9900400207     Document Type: Review

References (68)

1. Hearse DJ, Humphrey SM, Nayler WG, Slade A, Border D. Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 1975; 7: 315-24.
2. Horwitz LD, Fennessey PV, Shikes RH, Kong Y. Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation 1994; 89: 1792-801.
3. Connolly ES Jr, Winfree CJ, Springer TA et al. Cerebral protection in homozygous null Icam-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209-16.
4. McCord JM. Oxygen-derived free radicals in post-ischemic tissue injury. N Engl J Med 1985; 312: 159-63.
5. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide: general properties and effect of hyperbaric oxygen. Biochem J 1973; 134: 707-16.
6. Horwitz LD, Leff JA. Catalase and hydrogen peroxide cytotoxicity in cultured cardiac myocytes. J Mol Cell Cardiol 1995; 27: 909-15.
7. Floyd RA, Lewis CA. Hydroxyl free radical formation from hydrogen peroxide by ferrous iron-nucleotide complexes. Biochemistry 1983; 22: 2645-49.
8. Graf E, Mahoney JR, Bryant RG, Eaton JW. Iron-catalyzed hydroxyl formation. J Biol Chem 1984; 259: 3620-24.
9. Lesnefsky EJ, Ye J. Exogenous intracellular, but not extracellular, iron augments myocardial reperfusion injury. Am J Physiol 1994; 266: H384-92.
10. Voogd A, Sluiter, Koster JF. The increased susceptibility to hydrogen peroxide of the (post-)ischemic rat heart is associated with the magnitude of the low molecular weight iron pool. Free Radic Biol Med 1994; 16: 453-58.
11. Byler RM, Sherman NA, Wallner JS, Horwitz LD. Hydrogen peroxide cytotoxicity in cultured cardiac myocytes is iron dependent. Am J Physiol 1994; 266: H121-27.
12. Lesnefsky EJ, Dauber IM, Horwitz LD. Altered myocardial sulfhydryl pools during reperfusion in canine models of infarcted and stunned myocardium. Circ Res 1991; 68: 605-13.
13. Farber NE, Vercellotti GM, Jacobs HS, Pieper GM, Gross GJ, Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart. Circ Res 1988; 63: 351-60.
14. Williams RE, Zweier JL, Flaherty JT. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation 1991; 83: 1006-14.
15. Reddy BR, Kloner RA, Przyklenk K. Early treatment with deferoxamine limits myocardial ischemia/reperfusion injury. Free Radic Biol Med 1989; 7: 45-52.
16. Lesnefsky EJ, Repine JE, Horwitz LD. Deferoxamine pretreatment reduces canine infarct size and oxidative injury. J Pharmacol Exp Ther 1990; 253: 1103-109.
17. Summers MR, Jacobs A, Tudway B, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 1979; 42: 547-55.
18. Lloyd JB, Cable H, Rice-Evans C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol 1991; 41: 1361-63.
19. Gobin J, Moore CH, Reeve JR Jr, Wong DK, Gibson BW, Horwitz MA. Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA 1995; 92: 5189-93.
20. Horwitz LD, Sherman NA, Kong Y, et al. Lipophilic siderophores of mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci USA 1998; 95: 5263-68.
21. Gordeuk V, Mukiibi J, Hasstedt SI et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95-100.
22. Pippard MJ, Wetherall DJ. Iron absorption in non-transfused iron loading anemias. Prediction of risk of iron loading, and response to iron chelation treatment in ß-thalassemia intermedia and congenital sideroblastic anemias. Haematologica 1984; 17: 404-14.
23. Ward JH, Kushner JP, Kaplan J. Regulation of HeLa cell transferrin receptor number. J Biol Chem 1982; 257: 10317-23.
24. Munro HN, Lindner MC. Ferritin structure, biosynthesis and function. Physiol Rev 1978; 58: 317-96.
25. Klausner R, Roualt TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993; 72: 19-28.
26. Olson LJ, Edwards WD, Holmes DR, Miller FA, Nordstrom LA, Baldus WP. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J Am Coll Cardiol 1989; 131: 116-20.
27. Trousseau A. Glycosurie; diabete sucre. Clinique médicale ce l'Hotel-Dieu de Paris 1865; 2: 663-98.
28. Feder JN, Gnirk A, Thomas W et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-108.
29. Edwards CQ, Griffin LM, Goldyar D, Drummond C, Skolnick MH, Kusher JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-62.
30. Aldouri MA, Wonke B, Hoffbrand AV et al. High incidence of cardiomyopathy in beta thalassemia patients receiving regular transfusions and iron chelation: reversal by intensified chelation. Acta Hematol 1990; 84: 113-17.
31. Fitchett DH, Coltart DJ, Littler WA et al. Cardiac involvement in secondary hemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14: 719-24.
32. Olson LJ, Edwards WD, McCall JT et al. Cardiac iron deposition from idiopathic hemochromatosis: histologic and analytical assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10: 1239-43.
33. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med 1971; 51: 209-21.
34. Skinner C, Kenmure ACF. Hemochromatosis presenting as congestive cardiomyopathy and responding to venesection. Br Heart J 1973; 35: 466-68.
35. Wasserman AJ, Richardson DW, Baird CL, Wyso EM. Cardiac hemochromatosis simulating constrictive pericarditis. Am J Med 1962; 32: 316-23.
36. Candell-Riera J, Lu L, Serés L et al. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol 1983; 52: 824-29.
37. Dabestani A, Child JS, Henze E et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol 1984; 54: 153-59.
38. Waxman S, Eustace S, Hartnell GG. Myocardial involvement in primary hemochromatosis demonstrated by magnetic resonance imaging. Am Heart J 1994; 128: 1047-49.
39. Dover GJ, Valle D. Therapy for β-thalassemia? a paradigm for the treatment of genetic disorders. N Engl J Med 1994; 331: 609-10.
40. Wolfe L, Olivieri N, Sallan D et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312: 1600-603.
41. Olivieri NF, Nathan DG, MacMillan JH et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331: 574-78.
42. Brittenham GM, Griffith PM, Nienhuis AW et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-73.
43. Freeman AP, Giles RW, Berdoukas VA et al. Sustained normalization of cardiac function by chelation therapy in thalassemia major. Clin Lab Haematol 1989; 11: 299-307.
44. Freeman AP, Giles RW, Berdoukas VA et al. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med 1983; 99: 450-54.
45. Carmine TC, Evans P, Bruchelt G et al. Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Lett 1995; 94: 219-26.
46. Powis G. Free radical formation by antitumor quinones. Free Radic Biol Med 1989; 6: 63-101.
47. Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27.
48. Hershko C, Link G, Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993; 11: 207-14.
49. Gordeuk VR, Brittenham GM. Bleomycin-reactive iron in patients with acute non-lymphocytic leukemia. FEBS Lett 1992; 308: 4-6.
50. Beare S, Steward WP. Plasma free iron and chemotherapy toxicity. Lancet 1996; 347: 342-43.
51. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; i: 1293-94.
52. Araujo JA, Romano EL, Brito BE et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1172-80.
53. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995; 95: 2104-10.
54. Gutteridge JMC, Richmond R, Halliwell B. Inhibition of the iron-catalyzed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J 1979; 184: 469-72.
55. cdAz kinase. Blood 1995; 86: 2268-80.
56. Porreca E, Ucchino S, Di Febbo C et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14: 299-304.
57. Hagen PO, Davies MG, Schuman RW, Murray JJ. Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. J Vasc Res 1992; 29: 405-409.
58. Pang J-HS, Jiang M-J, Chen Y-L et al. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest 1996; 97: 2204-12.
59. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-11.
60. Berge LN, Bonaa KH, Norday A. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arterioscler Thromb 1994; 14: 857-61.
61. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid arteriosclerosis: prospective results from the Bruneck study. Circulation 1997; 96: 3300-307.
62. Magnusson MK, Sigfusson N, Sigvaldason H et al. Low iron binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89: 102-108.
63. Rauramaa R, Vaisanen S, Mercuri M et al. Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. Eur Heart J 1994; 15: 1020-27.
64. Moore M, Folsom AR, Barnes RW et al. No association between serum ferritin and asymptomatic carotid atherosclerosis. Am J Epidemiol 1995; 141: 719-23.
65. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994; 89: 2915-18.
66. Morrison HI, Semenciw RM, Mao Y. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994; 5: 243-46.
67. Ascherio A, Willett WC, Rimm EB. Dietary iron intake and risk of coronary artery disease among men. Circulation 1994; 89: 969-74.
68. Reunanen A, Takkunen H, Knekt P et al. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995; 238: 223-30.